Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells
Cell Communication and Signaling · 24.10.2024 · 22 (1)
DOI: 10.1186/s12964-024-01893-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Communication and Signaling, online erschienen am 24.10.2024. Verfasst von Kyoung-Seok Oh und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms, Nucleotidyltransferases, Membrane Proteins, Trastuzumab. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Although the efficacy of trastuzumab deruxtecan (T-DXd) against HER2-positive gastric cancers (GCs) has driven its clinical application, the precise mechanisms governing its immunomodulatory role remain unclear. In this study, we examined the immune-related mechanisms of action of T-DXd in GC cells. T-DXd exhibited potent antitumor effects in GC cells across diverse HER2 expression levels by inducing DNA damage and apoptosis. Activation of the DNA damage response by T-DXd led to increased PD-L1 expression. RNA-Seq analysis revealed that T-DXd modulated immune-related pathways, resulting in the upregulation of genes associated with inflammation and IFN signaling. Importantly, T-DXd activated the cGAS-STING pathway, inducing an IFN-I response in HER2-positive GC cells. Furthermore, T-DXd activated dendritic cells via the cancer cell-intrinsic cGAS-STING-IFN axis and enhanced PBMC-mediated tumor cell killing by activating CD8 + T cells. These findings provide valuable insights into the role of the cytosolic DNA sensing pathway in the action of T-DXd and offer a compelling rationale for combining T-DXd with immune checkpoint blockade therapies in GC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea.
- Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, 03080, Korea.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Korea.
- Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Korea. ohdoyoun@snu.ac.kr.
- Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, 03080, Korea. ohdoyoun@snu.ac.kr.
- Department of Internal Medicine, Seoul National University Hospital, Seoul, 03080, Korea. ohdoyoun@snu.ac.kr.
Zitieren
APA
Oh, K. S., Nam, A. R., Bang, J. H., Jeong, Y., Choo, S. Y., Kim, H. J., Lee, S. I., Kim, J. M., Yoon, J., Kim, T. Y., & Oh, D. Y. (2024). Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Communication and Signaling, 22(1). https://doi.org/10.1186/s12964-024-01893-3
Vancouver
Oh KS, Nam AR, Bang JH, Jeong Y, Choo SY, Kim HJ, et al. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells. Cell Communication and Signaling. 2024;22(1). doi:10.1186/s12964-024-01893-3
BibTeX
@article{Oh2024,
author = {Oh, Kyoung-Seok and Nam, Ah-Rong and Bang, Ju-Hee and Jeong, Yoojin and Choo, Sea Young and Kim, Hyo Jung and Lee, Su In and Kim, Jae-Min and Yoon, Jeesun and Kim, Tae-Yong and Oh, Do-Youn},
title = {Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells},
journal = {Cell Communication and Signaling},
year = {2024},
volume = {22},
number = {1},
doi = {10.1186/s12964-024-01893-3}
}
EUVIMED